Review Article

Effect of Traditional Chinese Medicine Bufei Granule on Stable Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis Based on Existing Evidence

Yihua Fan,1 Xinyan Wen,2 Qiang Zhang,3 Fangyuan Wang,1 Qing Li,3 Xinju Li,1 and Yi Guo

1Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
2The First Teaching Hospital of Tianjin University of TCM, Tianjin 300193, China
3Department of Oncology, Army Medical Center of PLA, Chongqing 400042, China

Correspondence should be addressed to Xinju Li; mars402498971@126.com and Yi Guo; guoyi_168@163.com

Received 30 October 2019; Accepted 10 January 2020; Published 7 February 2020

Copyright © 2020 Yihua Fan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This systematic review and meta-analysis aimed at evaluating the effect of traditional Chinese medicine (TCM) Bufei granule on stable chronic obstructive pulmonary disease (COPD). We retrieved data from PubMed, Web of Science, EMBASE, the Cochrane Central Register of Controlled Trials, CNKI, Wanfang, and WeiPu (VIP) for studies focusing on whether the TCM Bufei granule would be effective in treating stable COPD. No language restriction and blinding were used. All trials involved were examined based on the standards of the Cochrane Handbook, and Review Manager 5.3 software was applied for analyzing data. We included four studies involving 599 patients with stable COPD. When compared to placebo treatment, TCM Bufei granule intervention exhibited improvement in the forced expiratory volume in one second (FEV₁) (standardized mean difference (SMD) = 0.70; range, 0.50–0.91; I² = 0%), forced vital capacity (FVC) (SMD = 0.43; range, 0.23–0.62; I² = 0%), FEV₁ percentage of predicted value (FEV₁%) (SMD = 0.57; range, 0.38–0.76; I² = 4%), and FEV₁/FVC (SMD = 0.69; range, 0.50–0.87; I² = 0%). There was a statistically significant difference in St George’s Respiratory Questionnaire scores between the TCM Bufei granule and placebo treatments (SMD = −1.29; range, −2.32 to −0.26, I² = 97%). None of the studies reported any adverse events. Therefore, TCM Bufei granule intervention could help in improving the lung function and quality of life in patients with stable COPD.

1. Introduction

Chronic obstructive pulmonary disease (COPD) is a common health issue worldwide [1–3] due to its increasing prevalence, financial burden, and associated morbidity. According to the projection for 2020, it will be among the top three diseases in the world responsible for deaths [4]. In China, COPD will be responsible for the deaths of 65 million people in 30 years from 2003, mainly due to tobacco smoking and use of solid fuel [5]. Although evidence-based treatment has been recommended for dealing with COPD, including short-acting bronchodilators, long-acting bronchodilators (LABAs), inhaled glucocorticosteroids, and low-dose and slow-release theophylline [6], these treatments are inevitably associated with several side effects [7, 8]. These unwanted side effects could cause some people with COPD to explore other treatment options. Therefore, it is essential to design better strategies and interventions for COPD.

Traditional Chinese medicine (TCM) has been the treatment for COPD for many years. In China, many COPD patients are treated with TCM modalities daily. Studies have shown the positive effects of using TCM drugs in stable COPD [9–14]. However, they lacked reasonable research scheme design and were limited to one medical centre or were without placebo control.

In the TCM theory, COPD affects the lung in the initial phase of the pathophysiology as well as the progression of the disease. COPD ultimately causes Ben-root deficiency...
Evidence-Based Complementary and Alternative Medicine

Biao-branch excess syndrome, which is considered as Qi deficiency of the lungs, spleen, and kidneys, along with phlegm retention and blood stasis [15, 16]. The pathogenesis of COPD can be explained by the deficiency of anti-pathogenic Qi and excess of pathogenic Qi. Thus, the idea of the treatment is to focus on strengthening vital Qi, dispelling blood stasis, and resolving phlegm. Bufei granule has been developed according to the treatment principle that aims at enhancing the immune functioning of the lungs and ZangFu organs. This protection can prevent disease progression in COPD patients [15]. Several clinical trials [15, 17–19] have indicated the therapeutic effect of TMC Bufei granule in COPD patients with respect to improving the patient’s wellbeing and lung function. However, there is no design that systematically assesses the quality of these trials, and their results remain controversial and inconclusive. The objective of this review was to compare the positive impact of TCM Bufei granule intervention and placebo intervention in adults with stable COPD.

2. Materials and Methods

2.1. Search Strategy. Randomized controlled studies reported through September 9, 2019, were systematically searched in PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science, CNKI, Wanfang, and VIP databases. The search terms mainly included COPD, chronic obstructive pulmonary disease, Bufei granule, and Bufei keli (Table S1). Other reference materials and relevant articles were also searched. All literature review was carried out by the two investigators (Yihua Fan and Xinyan Wen). When disagreements arose, a third investigator (Qiang Zhang) was engaged until an agreement was reached.

2.2. Inclusion and Exclusion Criteria. Inclusion criteria were as follows:

1. Randomized controlled studies on Bufei granule treatment of stable COPD
2. Stable COPD patients diagnosed as per the criteria for diagnosis, management, and prevention of COPD as reported by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) [20]; according to the pulmonary function test (GOLD guide application of bronchiectasis drugs), FEV₁ ≥30% and <80% predicted value and FEV₁/FVC <70% diagnosed as stable moderate to severe COPD (grade 2 GOLD, GOLD level 3) and stable COPD patients with stable symptoms such as cough, sputum production, or breathlessness
3. The intervention of the treatment group included conventional therapy and Bufei granule
4. Conventional therapy and placebo granule were used to treat the control group
5. Outcomes of our study included St George’s Respiratory Questionnaire (SGRQ) score [21], FEV₁, FVC, FEV₁/predicted value (FEV₁%), and FEV₁/FVC

Exclusion criteria were as follows:

- Expert comment, conference report, republished literature, or case reports were excluded

2.3. Study Selection. Two investigators (Yihua Fan and Xinyan Wen) independently selected the studies using Endnote X7 software based on the predetermined criteria. First, they eliminated duplication among the different databases from the initial aggregated search results. Second, by reviewing the titles of studies and their abstracts, seemingly irrelevant studies were excluded. Third, two investigators screened the full texts of the potential related studies and excluded unqualified studies. Both investigators independently cross-checked the selection results of the studies. Any disagreements during the study period were discussed, and a third investigator (Qiang Zhang) was approached for consulting and decision making if the problem was not resolved.

2.4. Data Extraction. Following the literature selection, the two investigators (Yihua Fan and Xinyan Wen) separately used an extraction sheet to extract data from the studies, including the first author’s name, year of publication, sample size, participants’ average age, intervention measures, time of intervention, and outcome indicators. We also interacted with the authors by sending e-mails or calling on the phone, in order to gather further information that was not included in the literature. For continuous outcomes, standard deviations and means were extracted.

2.5. Quality Evaluation. Quality of research studies was assessed independently by two investigators (Yihua Fan and Xinyan Wen) using the risk of bias evaluation for randomized clinical trials in the systematic Cochrane Reviews. Evaluation items included random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcomes assessment, incomplete outcome data, selective reporting, and other biases. The third investigator (Qiang Zhang) resolved the discrepancies. The meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Table S2) [22].

2.6. Statistical Analyses. All statistical analyses were carried out using Review Manager 5.3 software (The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). The results were presented as the standardized mean difference (SMD) with the 95% confidence interval (95% CI). The clinical heterogeneity of the included studies was measured by the χ² test. If I² was <50%, the heterogeneity among studies was assumed to be small, and we used the fixed-effects model for data analysis. If heterogeneity was detected (I² ≥50%), we chose the random-effects model or used only qualitative descriptions. The stability and reliability of the meta-analysis were evaluated by sensitivity analysis. Egger’s and Begg’s tests were used for the evaluation of potential publication bias.
3. Results

3.1. Search Results. Our search scheme yielded 154 citations, and additional four citations were identified by examining reference lists of relevant kinds of literature. After removing duplicates and reviewing abstracts, 15 full texts were obtained and four of them [15, 17–19] were part of the final analysis (Figure 1).

3.2. Characteristics and Methodological Quality of the Eligible Studies. The characteristics of the four studies are described in Table 1, and they included 599 patients [15, 17–19]. All studies were conducted in China. Three studies lasted for 12 weeks [15, 17, 19], while one lasted for 30 days [18]. The quality and risk of bias assessment of the involved studies are described in Figure 2.

3.3. Synthesis of Results

3.3.1. Pulmonary Function. Two studies [15, 17] reported FEV1 data. Total meta-analysis showed that the effect of Bufei granule was better than that of the placebo (SMD = 0.70; range, 0.50–0.91; I² = 0%). Two studies [15, 17] used FVC as the outcome. The pooled analysis revealed a statistically significant improvement in the FVC with TCM Bufei granule as compared to that of the placebo treatment (SMD = 0.43; range, 0.23–0.62; I² = 0%). Three studies [15, 17, 19] reported FEV1% data. Total meta-analysis showed that Bufei granule had a better effect than the placebo treatment (SMD = 0.57; range, 0.38–0.76; I² = 4%). Three studies [15, 17, 19] used FEV1/FVC as the outcome, and the pooled analysis showed a statistically significant improvement in the FEV1/FVC with TCM Bufei granule than that of the placebo treatment (SMD = 0.69; range, 0.50–0.87; I² = 0%). Here, Figure 3 shows the efficacy of Bufei granule in stable COPD patients.

3.4. St George’s Respiratory Questionnaire Score. Four studies [15, 17–19] used the SGRQ score, and a reduction in the SGRQ score implied an improvement in the patient’s wellbeing. The TCM Bufei granule treatment caused a statistically significant improvement in health-related quality of life as compared to the placebo (SMD = −1.29; range, −2.32 to −0.26; I² = 97%). The result of the SGRQ score analysis is presented in Figure 4.

3.5. Adverse Events. None of the studies reported any adverse events.

3.6. Sensitivity Analysis. The stability and reliability of the meta-analysis were evaluated by sensitivity analysis. When the study by Guo et al. [15] was excluded for the SGRQ score, the result was reversed, thus indicating that the study result was not stable. Other outcome measures were stability and reliability.

3.7. Publication Bias. Begg’s funnel plot (Figure S1) and Egger’s test were performed to evaluate the publication bias of the included studies. The results showed no statistically significant difference (Begg’s test P = 0.497; Egger’s test P = 0.338).

4. Discussion

Previously, smoking cessation was considered the only way to treat the COPD progression because it caused a reduction in FEV1 and mortality rates. However, the pharmacotherapy for COPD has significantly improved in the past decade [23, 24] due to the accessibility of inhalational corticosteroids [25], fixed combinations of inhaled corticosteroids, long-acting β2-agonists (LABAs) [7], and long-acting anticholinergic or muscarinic antagonists [26], which have improved the patients’ treatment outcomes. TCM has been used to treat COPD for many years, especially in China. TCM believes that the main pathogenesis of COPD in the stable stage is a Qi deficiency in the lungs, spleen, and kidneys. This is because of the long period of attack, long exogenous pathogenic factors in the lung, lung Qi damage, phlegm turbidity and heat stasis, and damage to vital-qi. Therefore, the main treatment in the stable stage is aimed at strengthening the vital-Qi.

In the stable phase of COPD, the pathogenesis of COPD is the deficiency of antipathogenic Qi and excess of pathogenic Qi. Its treatment should be based on strengthening vital-qi, eliminating blood stasis, resolving phlegm to relieve asthma, and improving the function of viscera to enhance the defensive capacity, thereby effectively preventing further development of the disease. Bufei granule is a decoction of the Bufei decoction in “Qianjin Yaofang for Emergency Preparedness” and Jinshui Liujun decoction in “Jingyue Quanshu New Eight Arrangements,” composed of Danshen, Shudihuang, Shanzhuyu, Mahuang, Chenpi, etc. [17]. Its main functions include invigorating the spleen, nourishing the kidneys, invigorating the lungs, removing blood stasis, resolving phlegm, and relieving asthma. Modern studies [15, 17, 27] have shown that Bufei granule can downregulate the levels of proinflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), and transformation growth factor-1β (TGF-β) in the alveolar lavage fluid; upregulate the expression of anti-inflammatory cytokines interleukin-4 (IL-4) and interleukin-10 (IL-10); inhibit the inflammatory response of lung tissue; and exert a clinically therapeutic effect. Li et al. [10] showed that Bufei granule could decrease the level of serum soluble ST2 by increasing the levels of serum interleukin-33 (IL-33), IL-4, and IL-10, which in turn enhances the anti-inflammatory ability of the body. Therefore, by analyzing the mechanism of Bufei granule in modern experiments, it can be inferred that it has important research value in the treatment of COPD. Our study collected the latest randomized, double-blind, and placebo-controlled trials and conducted a comprehensive quantitative analysis.

This systematic review demonstrates the present evidence regarding Bufei granule in the treatment of COPD. Bufei granule along with conventional medical treatment...
could improve lung function and the quality of life in COPD patients better as compared to placebo plus conventional medicine. The FEV₁, FVC, FEV₁%, and FEV₁/FVC are important indicators for evaluating lung function. The decrease in FEV₁ indicates poor lung function, while increase in FEV₁ indicates improvement in COPD pulmonary function. However, single evaluation of FEV₁ cannot evaluate the postdiastolic response in patients accurately. Therefore, FEV₁, FVC, FEV₁%, and FEV₁/FVC parameters were used to evaluate the pulmonary function better. The efficacy of Bufeı granule is according to the recommended treatment standard of GOLD, which can alleviate current symptoms and risks [22]. The SGRQ score not only measures the patient’s condition change, but also assesses the patient’s psychological state. It also has a good correlation with FEV₁, FEV₁%, FEV₁/FVC, and clinical symptoms of patients and further reflects their social activities, daily life, and psychological state. Moreover, some indicators have little effect on the score, such as racial factors [23]. This systematic review shows that Bufeı granule causes a statistically significant improvement in the SGRQ score as compared to the placebo. These outcomes seemed promising.

Table 1: Description of selected studies.

| Study            | Sample size | Age               | Interventions          | Intervention time | Indicators                                                                 |
|------------------|-------------|-------------------|------------------------|-------------------|-----------------------------------------------------------------------------|
| Sun et al. [18]  | 69          | 60.81 ± 8.18      | Bufeı granule          | 30 days           | SGRQ score                                                                 |
| Guo et al. [17]  | 136         | 61.89 ± 5.56      | Bufeı granule          | 12 weeks          | FEV₁; FVC; FEV₁/predicted value; SGRQ score                                 |
| Yang [19]        | 34          | 67.7              | Bufeı granule          | 12 weeks          | FEV₁; FVC; FEV₁/predicted value; SGRQ score                                 |
| Guo et al. [15]  | 69          | NA                | Bufeı granule          | 12 weeks          | FEV₁; FVC; FEV₁/predicted value; SGRQ score                                 |

Abbreviations: NA, data not available; SGRQ, St George’s Respiratory Questionnaire; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias

Guo 2014
Guo 2018
Sun 2012
Yang 2015

Figure 2: Risk of bias summary.

| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight (%) | Std. mean difference IV. random. 95% CI | Std. mean difference IV. random. 95% CI |
|-------------------|-------------------|----|-------|--------------|----|-------|------------|-----------------------------------|-----------------------------------|
| **FEV1**          |                   |    |       |              |    |       |            |                                   |                                   |
| Guo 2014          | 1.4               | 0.6 | 69    | 0.5         | 61 |       | 32.3       | 0.72 [0.36, 1.07]                  |                                   |
| Guo 2018          | 1.52              | 0.49| 136   | 0.39        | 135|       | 67.7       | 0.70 [0.45, 0.94]                  |                                   |
| Subtotal (95% CI) |                   |    |       |              |    |       | 100.0      | 0.70 [0.50, 0.91]                  |                                   |
| **FVC**           |                   |    |       |              |    |       |            |                                   |                                   |
| Guo 2014          | 2.3               | 0.9 | 69    | 0.7         | 61 |       | 32.1       | 0.49 [0.14, 0.84]                  |                                   |
| Guo 2018          | 2.42              | 0.82| 136   | 0.68        | 135|       | 67.9       | 0.40 [0.16, 0.64]                  |                                   |
| Subtotal (95% CI) |                   |    |       |              |    |       | 100.0      | 0.43 [0.23, 0.62]                  |                                   |
| **SGRQ score**    |                   |    |       |              |    |       |            |                                   |                                   |
| Guo 2014          | 62.5              | 20.8 | 69 | 7.4        | 61 |       | 27.8       | -1.18 [-1.56, 0.81]                |                                   |
| Guo 2018          | 64.08             | 10.47| 136 | 10.27      | 135|       | 58.2       | -0.66 [0.41, 0.90]                 |                                   |
| Subtotal (95% CI) |                   |    |       |              |    |       | 100.0      | 0.66 [0.31, 1.01]                  |                                   |

Figure 3: Meta-analysis of pulmonary function.

| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight (%) | Std. mean difference IV. random. 95% CI | Std. mean difference IV. random. 95% CI |
|-------------------|-------------------|----|-------|--------------|----|-------|------------|-----------------------------------|-----------------------------------|
| **FEV1/FVC**      |                   |    |       |              |    |       |            |                                   |                                   |
| Guo 2014          | 26                | 8  | 69    | 12          | 61 |       | 25.1       | -1.18 [-1.56, 0.81]                |                                   |
| Guo 2018          | 20                | 5  | 136   | 11          | 135|       | 25.3       | -2.69 [-3.02, -2.36]               |                                   |
| Sun 2012          | 32.46             | 15.27| 69 | 15.6       | 61 |       | 25.2       | -0.58 [-0.93, -0.22]               |                                   |
| Yang 2015         | 20                | 6  | 34    | 8           | 34 |       | 24.5       | -0.70 [-1.19, -0.21]               |                                   |
| Subtotal (95% CI) |                   |    |       |              |    |       | 100.0      | -1.29 [-2.32, -0.26]               |                                   |
| **SGRQ score**    |                   |    |       |              |    |       |            |                                   |                                   |
| Guo 2014          | 26                | 8  | 69    | 12          | 61 |       | 25.1       | -1.18 [-1.56, 0.81]                |                                   |
| Guo 2018          | 20                | 5  | 136   | 11          | 135|       | 25.3       | -2.69 [-3.02, -2.36]               |                                   |
| Sun 2012          | 32.46             | 15.27| 69 | 15.6       | 61 |       | 25.2       | -0.58 [-0.93, -0.22]               |                                   |
| Yang 2015         | 20                | 6  | 34    | 8           | 34 |       | 24.5       | -0.70 [-1.19, -0.21]               |                                   |

Total (95% CI) 308 291 100.0 -1.29 [-2.32, -0.26]

Figure 4: Meta-analysis of SGRQ score.
and encouraging of the combination treatment of Bufeif granule and conventional treatment to help improve lung function.

This study had some limitations. First, although the quality of the randomized controlled trials included in the meta-analysis was high, pulmonary function test indicators and the number of trials evaluated were limited. The conclusion needs further verification. At the same time, the sensitivity analysis of the SGRQ score was performed by a one-by-one elimination. This could check the stability and reliability of the results. When the study by Guo et al. [15] was excluded, the results of the meta-analysis were reversed and their conclusions would need further verification. Second, there are only a few articles on Bufeif granule treatment for stable COPD published in English journals. Only one article was collected in this study. Its limited evaluation outside China has affected the external effectiveness of Bufeif granule treatment of stable COPD. Although this study has these limitations, it has potential significance. Bufeif granule treatment can be effectively used in the intervention of stable COPD.

5. Conclusions

TCM Bufeif granule treatment therapy may be associated with the improvement of lung function and better quality of life in COPD patients. Bufeif granule could become a new treatment strategy in the intervention of stable COPD.

Disclosure

Yihua Fan and Xinyan Wen are co-first authors.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Yihua Fan and Xinyan Wen contributed equally to this work.

Acknowledgments

The authors would like to thank Fanqi Sun (University of Sydney, Sydney, Australia) for the help with the English language. This research was supported by the National Basic Research Program of China under Grant no. 2014CB543201.

Supplementary Materials

Table S1: search strategy. Table S2: the PRISMA checklist. Figure S1: the funnel plot for publication bias. (Supplementary Materials)

References

[1] M.-H. Li, L.-C. Fan, B. Mao et al., "Short-term exposure to ambient fine particulate matter increases hospitalizations and mortality in COPD," Chest, vol. 149, no. 2, pp. 447–458, 2016.

[2] S. Lim, D. C. Lam, A. R. Muttalif et al., "Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey," Asia Pacific Family Medicine, vol. 14, no. 1, p. 4, 2015.

[3] X.-J. Li, Y. Kang, R.-R. Wang et al., "Effects of safflower yellow on acute exacerbation of chronic obstructive pulmonary disease: a randomized, controlled clinical trial," Evidence-Based Complementary and Alternative Medicine, vol. 2019, Article ID 5952174, 14 pages, 2019.

[4] C. Liu and P. O. Girodet, "Epidemiology of COPD," European Respiratory Review, vol. 18, no. 114, pp. 213–221, 2009.

[5] H.-H. Lin, M. Murray, T. Cohen, C. Colijn, and M. Ezzati, "Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study," The Lancet, vol. 372, no. 9648, pp. 1473–1483, 2008.

[6] Q. Amir, T. J. Wilt, S. E. Weinerberger et al., "Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American college of physicians, American college of chest physicians, American thoracic society, and European respiratory society," Annals of Internal Medicine, vol. 147, no. 9, pp. 633–638, 2011.

[7] P. M. A. Calverley, J. A. Anderson, B. Celli et al., "Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease," New England Journal of Medicine, vol. 356, no. 8, pp. 775–789, 2007.

[8] L.-P. G. Ming Ren, X. Sun, Y. Qiao et al., "Based on the process management of traditional Chinese medicine comprehensive intervention method on outcomes in patients with mild/moderate chronic obstructive pulmonary disease: study protocol for a practical randomized controlled trial," TMR Integrative Medicine, vol. 2, no. 4, pp. 197–201, 2018.

[9] S. Y. Li, J. S. Li, M. H. Wang et al., "Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-center, open-label, randomized, controlled study," BMC Complementary & Alternative Medicine, vol. 12, no. 1, p. 197, 2012.

[10] J. Li, S. Y. Li, and X. Q. Yu, "Bufeif Yisheng granule combined with acupoint-sticking therapy in patients with stable chronic obstructive pulmonary disease: study protocol of a multicenter, randomized, double-blind, active-controlled trial," Journal of Chinese Integrative Medicine, vol. 9, no. 12, pp. 1312–1318, 2011.

[11] H. Zhang and E. Chao, "Clinical trial of tiaboufeishen capsules for treating chronic obstructive pulmonary disease at stable stage," Journal of Beijing University of Traditional Chinese Medicine, vol. 26, no. 2, pp. 53–56, 2003.

[12] C. L. Feng and W. P. Wu, "Effect of TCM therapy by principle for nourishing qi, activating blood circulation and resolving phlegm on quality of life of patients with chronic obstructive pulmonary disease," Chinese Journal of Integrated Traditional & Western Medicine, vol. 25, no. 9, pp. 829–831, 2005.

[13] L. Wu, Y. Chen, Y. Xu et al., "Oral Huangqi formulae for stable chronic obstructive pulmonary disease: a systematic review and meta-analysis," Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 705315, 14 pages, 2013.

[14] X. Duan, J. Wu, X. Huang et al., "Comparative efficacy of Chinese herbal injections for treating acute exacerbation of chronic obstructive pulmonary disease: a bayesian network meta-analysis of randomized controlled trials," Evidence-Based Complementary and Alternative Medicine, vol. 2018, Article ID 7942936, 11 pages, 2018.

[15] S. Guo, Z. Sun, E. Liu et al., "Effect of Bufeif granule on stable chronic obstructive pulmonary disease: a randomized, double
blinded, placebo-controlled, and multicenter clinical study,” Journal of Traditional Chinese Medicine, vol. 34, no. 4, pp. 437–444, 2014.

[16] T. Xie and W. Zhang, “Progress on Bufei Jianpi Yishen therapy for COPD in stable phase,” Journal of Changchun University of Traditional Chinese Medicine, vol. 30, no. 1, pp. 173–176, 2014.

[17] S. Guo, Z. Sun, Y. Li, Q. Wu, J. Feng, and D. Zhao, “Effect of Bufei granules on the serum IL-33/sST2 axis and related inflammatory cytokines in mild-to-moderate chronic obstructive pulmonary disease stable phase patients: a multicenter, double-blinded, randomized controlled trial,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 38, no. 9, pp. 1034–1039, 2018.

[18] Z. Sun, M. Fu, Y. Li, Q. Wu, E. Liu, and J. Feng, “Effects of Bufei granules on quality of life in patients with stable chronic obstructive pulmonary disease,” Journal of Traditional Chinese Medicine, vol. 53, no. 11, pp. 930–932, 2012.

[19] X. Yang, “Effect of Bufei granules on stable chronic obstructive pulmonary disease measured by questionnaire scores and forced expiratory volume,” Chinese Traditional Patent Medicine, vol. 37, no. 10, pp. 2146–2149, 2015.

[20] Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2018, http://www.goldcopd.org.

[21] P. W. Jones, F. H. Quirk, and C. M. Baveystock, “The St George’s respiratory questionnaire,” Respiratory Medicine, vol. 85, no. 2, pp. 25–31, 1991.

[22] D. Moher, L. Shamseer, M. Clarke et al., “Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement,” BMJ, vol. 349, no. 1, p. g7647, 2015.

[23] D. Flenley, “Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema,” Archivos De Bronconeumología, vol. 18, no. 4, p. 414, 1976.

[24] T. L. Croxton and W. C. Bailey, “Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 4, pp. 373–378, 2006.

[25] R. A. Pauwels, C.-G. Löfdahl, L. A. Laitinen et al., “Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking,” New England Journal of Medicine, vol. 340, no. 25, pp. 1948–1953, 1999.

[26] D. Tashkin, B. Celli, and S. Senn, “A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial),” Revista Portuguesa De Pneumologia, vol. 15, no. 1, p. 137, 2009.

[27] S. Guo, J. Feng, J. Wu, Z. Hao, and Z. Sun, “Effects of Bufei granules on lung inflammation in mice with chronic obstructive pulmonary disease stable phase,” Liaoning Journal of Traditional Chinese Medicine, vol. 46, no. 6, pp. 1314–1317, 2019.